Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

During the first day of the 44 th Annual JP Morgan Healthcare Conference in San Francisco, a clear narrative emerged. With ...

US biotech Biogen (Nasdaq: BIIB) said the European Commission on January 12, 2026 granted marketing authorization for a ...

On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his ...

Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several ...

A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

In May 2022, The US FDA authorized the use of RADICAVA ORS (edaravone) in an oral formulation for the treatment of ALS.

One of North Carolina's largest biotechnology companies is expanding its operations with a $2 billion investment. Triangle eco-devo pipeline could bring thousands of jobs $700M investment bolsters ...

Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Discover the strategic reasons ...

AI-generated summary reviewed by our newsroom. Read our AI Policy. Biogen plans to beef up its Research Triangle Park operations with $2 billion in new local spending, the company announced Monday.